Cancer · 1991 · 146 citations · 18 references
MedicineHematologyInternal MedicineClinical PharmacologyHematopathologyHemostasisAntiplatelet TherapyAntithrombotic TherapyCoagulation AbnormalitiesPlatelet DisordersThrombosisThrombotic DisordersAntiplatelet DrugsHemorrhagic ManifestationsHemorrhagic PresentationPatient History AssessmentRetrospective Case StudySymptomatic Presentation
A retrospective study of 103 patients with essential thrombocythemia was carried out to evaluate the incidence of thrombohemorrhagic complications and establish whether there were any correlations between these events and clinical or laboratory data. At onset or during the course of the disease, 26 patients (25.2%) presented thrombotic and 12 (11.6%) hemorrhagic complications: among the latter, six patients had gastrointestinal bleeding during antiaggregant therapy. No significant correlations were observed between thrombohemorrhagic complications and platelet count, age, sex, platelet function, bleeding time, or therapeutic regimen. However, there was a statistically significant correlation between a positive patient history for thrombotic events and an increase in thromboses. In agreement with other authors, it is believed that the best approach in asymptomatic patients is strict surveillance without treatment. Chemotherapy and/or treatment with antiaggregant agents should be reserved for symptomatic patients or patients with a positive history for thrombotic events.
18
Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group.
Seamus Murphy, Harry Iland, David S. H. Rosenthal et al. · PubMed · 1986 · 485 citations
Bleeding and thrombosis in the myeloproliferative disorders
AI Schafer · Blood · 1984 · 428 citations · Full text
Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell
PJ Fialkow, GB Faguet, RJ Jacobson et al. · Blood · 1981 · 382 citations · Full text